收费全文 | 809篇 |
免费 | 47篇 |
国内免费 | 2篇 |
耳鼻咽喉 | 5篇 |
儿科学 | 4篇 |
妇产科学 | 2篇 |
基础医学 | 108篇 |
口腔科学 | 7篇 |
临床医学 | 47篇 |
内科学 | 255篇 |
皮肤病学 | 14篇 |
神经病学 | 91篇 |
特种医学 | 11篇 |
外科学 | 135篇 |
综合类 | 2篇 |
预防医学 | 5篇 |
眼科学 | 2篇 |
药学 | 22篇 |
肿瘤学 | 148篇 |
2023年 | 4篇 |
2022年 | 10篇 |
2021年 | 14篇 |
2020年 | 4篇 |
2019年 | 8篇 |
2018年 | 19篇 |
2017年 | 15篇 |
2016年 | 22篇 |
2015年 | 19篇 |
2014年 | 17篇 |
2013年 | 35篇 |
2012年 | 52篇 |
2011年 | 48篇 |
2010年 | 35篇 |
2009年 | 18篇 |
2008年 | 42篇 |
2007年 | 42篇 |
2006年 | 36篇 |
2005年 | 41篇 |
2004年 | 36篇 |
2003年 | 41篇 |
2002年 | 39篇 |
2001年 | 28篇 |
2000年 | 25篇 |
1999年 | 25篇 |
1998年 | 12篇 |
1997年 | 10篇 |
1996年 | 9篇 |
1995年 | 4篇 |
1994年 | 12篇 |
1993年 | 2篇 |
1992年 | 14篇 |
1991年 | 19篇 |
1990年 | 12篇 |
1989年 | 13篇 |
1988年 | 17篇 |
1987年 | 6篇 |
1986年 | 8篇 |
1985年 | 11篇 |
1984年 | 10篇 |
1983年 | 4篇 |
1981年 | 5篇 |
1979年 | 2篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1971年 | 2篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1966年 | 1篇 |
1901年 | 1篇 |
The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy in patient with tumor mutation burden-high (TMB-H) solid tumors and have been established as a third tumor-agnostic agent, making it necessary to develop the guideline prioritized for these patients. Clinical questions regarding medical care were formulated for patients with TMB-H advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. The current guideline describes three clinical questions and seven recommendations for whom, when, and how TMB should be tested, and what is recommended for patients with TMB-H advanced solid tumors. In this guideline, the committee proposed seven recommendations for performing TMB testing properly to select patients who are likely to benefit from immunotherapy.
相似文献Clinical trials have reported the efficacy of tropomyosin receptor kinase (TRK) inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors. The accumulated evidence of tumor-agnostic agent has made since TRK inhibitors were approved and used in clinical practice. Therefore, we have revised the ‘Japan Society of Clinical Oncology (JSCO)/Japanese Society of Medical Oncology (JSMO)-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese Society of Pediatric Hematology/Oncology (JSPHO)’.
MethodsClinical questions regarding medical care were formulated for patients with NTRK fusion-positive advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by JSCO, JSMO, and JSPHO voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done.
ResultsThe current guideline describes 3 clinical questions and 14 recommendations for whom, when, and how NTRK fusion should be tested, and what is recommended for patients with NTRK fusion-positive advanced solid tumors.
ConclusionThe committee proposed 14 recommendations for performing NTRK testing properly to select patients who are likely to benefit from TRK inhibitors.
相似文献